Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the association of Carfilzomib,
Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits
in patients with newly diagnosed Multiple Myeloma (MM).
Phase:
Phase 2
Details
Lead Sponsor:
European Myeloma Network Stichting Hemato-Oncologie voor Volwassenen Nederland